Drug Search Results
More Filters [+]

AZD-3161

Alternative Names: azd-3161, azd3161, azd 3161
Latest Update: 2011-04-12
Latest Update Note: Clinical Trial Update

Product Description

AstraZeneca was developing azd-3161, an injectable NaV1.7 blocker, for the treatment of mechanical pain sensitivity and axon reflex flare in normal and ultraviolet C irradiated skin (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01240148)

Mechanisms of Action: NaV1.7 Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD-3161

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Nociceptive Pain|Neuropathic Pain|Neuralgia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

D3780C00005

P1

Completed

Neuralgia|Neuropathic Pain|Nociceptive Pain

2011-03-01

Recent News Events

Date

Type

Title